Issue |
J Extra Corpor Technol
Volume 35, Number 4, December 2003
|
|
---|---|---|
Page(s) | 339 - 345 | |
DOI | https://doi.org/10.1051/ject/2003354339 | |
Published online | 11 August 2023 |
Use of Aprotinin in Patients Undergoing Deep Hypothermic Circulatory Arrest: A Review
University of Kansas Hospital, Kansas City, Kansas
* Address correspondence to: Suzanne Huffman, MPA, CCP, Chief of Perfusion Services, 3901 Rainbow Blvd., University of Kansas Hospital, Kansas City, KN 66160. Tel.: (913) 588-2894.
Received:
25
March
2002
Accepted:
18
July
2003
Hemostatic derangements continue to be a major clinical challenge during thoracic aortic surgery using deep hypothermic circulatory arrest despite advances in surgical and pharmacologic therapy. Aprotinin, a broad-based, nonspecific serine protease inhibitor has been advocated for prophylactic use in cardiac surgery to decrease perioperative blood loss and blood transfusions. Its efficacy has been documented in several studies throughout the United States and Europe. Currently, aprotinin is advocated for use in patients undergoing cardiopulmonary bypass in the course of coronary artery bypass graft surgery. A review of current studies is provided that examines aprotinin usage under deep hypothermic circulatory arrest.
Key words: aprotinin / cardiopulmonary bypass / circulatory arrest / renal insufficiency / thrombosis
© 2003 AMSECT
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.